Table 2.
Main meta-analysis results of LSD1 expression in cancer patients
| Analysis | Studies (N) | Number of patients | HR (95% CI) | P-value | Heterogeneity
|
||
|---|---|---|---|---|---|---|---|
| χ2 | I2 (%) | P-value | |||||
| OS | 9 | 1,149 | 1.80 (1.39–2.34) | 0.000 | 17.25 | 53.6 | 0.028 |
| Ethnicity | |||||||
| Asian | 8 | 888 | 1.97 (1.61–2.41) | 0.000 | 6.72 | 0.0 | 0.459 |
| HR estimate | |||||||
| Survival curves | 3 | 322 | 2.20 (1.63–2.96) | 0.000 | 1.13 | 0.0 | 0.567 |
| Reported directly | 5 | 764 | 1.63 (1.17–2.29) | 0.004 | 9.38 | 57.4 | 0.052 |
| Tumor type | |||||||
| Esophageal cancer | 3 | 372 | 1.77 (1.34–2.33) | 0.000 | 2.20 | 9.0 | 0.333 |
Abbreviations: LSD1, lysine-specific demethylase 1; OS, overall survival.